Calliditas secures FDA priority review for Tarpeyo full approval to treat IgAN
The sNDA is supported by the full data set from the Phase 3 randomised, double-blind, multicenter NefIgArd clinical…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
21 Aug 23
The sNDA is supported by the full data set from the Phase 3 randomised, double-blind, multicenter NefIgArd clinical…
21 Aug 23
The approval was based on positive results from the DELIVER Phase 3 trial in which Forxiga met its…
21 Aug 23
FDA granted the approval based on the data from the KINECT-HD Phase 3 study and the ongoing KINECT-HD2…
21 Aug 23
The 160-acre site owned by Reliance Life Sciences in Nashik is set to host manufacturing plants dedicated to…
21 Aug 23
Teclistamab, the first BCMA-targeting bispecific antibody to receive approval in Europe, maintained deep and durable responses, with reduced…
21 Aug 23
he funding will accelerate the clinical development of AST-004, a highly promising therapeutic candidate aimed at treating a…
18 Aug 23
Aquipta is a once-daily oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the prophylaxis of migraine in…
18 Aug 23
According to Moderna, these findings imply that the updated Covid-19 vaccine can successfully combat the Covid-19 variations that…
18 Aug 23
Coeptis gave Deverra around $570,000 in cash and 4,000,000 shares of its common stock for the immuno-oncology platform…
18 Aug 23
This decision was supported by newly released data from a Phase 2 dose discovery study in overweight or…